
Lonza and Bio*One Capital to Construct Cell Culture Facility
Lonza Group Ltd. (Basel, Switzerland, www.lonza.com) and Bio*One Capital (Centros, Singapore, www.bio1capital.com) have signed a joint venture - Lonza Biologics Tuas - to build a large-scale mammalian cell culture facility in Singapore for the manufacture of commercial biopharmaceuticals.
Lonza Group Ltd. (Basel, Switzerland,
Lonza Biologics Tuas, located in Tuas Biomedical Park, will have up to four mammalian bioreactor trains, each with a flexible capacity of 1,000 L up to 20,000 L. The facility will become operational in 2011. When fully completed, Lonza Biologics Tuas expects to hire approximately 350 people for the operation.
In February 2006 Lonza and Bio*Capital entered into an initial joint venture under the name Lonza Biologics Singapore Pte Ltd., to build an 80,000 liter large-scale mammalian biopharmaceutical production facility. This facility became 100% owned by Lonza upon the signing of the Lonza Biologics Tuas joint venture. Genentech has an exclusive option to acquire the Lonza owned facility between 2007 and 2012.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.